AVDL Jun 2019 5.000 call

OPR - OPR Delayed Price. Currency in USD
0.1000
0.0000 (0.00%)
As of 3:08PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0500
Open0.1000
Bid0.0000
Ask0.2500
Strike5.00
Expire Date2019-06-21
Day's Range0.1000 - 0.1000
Contract RangeN/A
Volume1
Open Interest1.26k
  • Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
    Zacks6 days ago

    Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

    Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

  • GlobeNewswire20 days ago

    Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced it will present two posters at the 33rd Annual Meeting of the Associated Professional Sleep Societies being held in San Antonio, Texas, from June 8-12, 2019. “Our once-nightly controlled-release sodium oxybate demonstrated lower overall peak plasma concentrations (Cmax) and similar total exposures (AUC), compared to twice-nightly sodium oxybate in a head-to-head study,” said Jordan Dubow, MD, Chief Medical Officer of Avadel Pharmaceuticals.

  • GlobeNewswire21 days ago

    Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointment of Gregory J. Divis as Chief Executive Officer and member of the Board of Directors. “Since being named Interim CEO at the beginning of 2019, Greg has done an excellent job leading the Company through rapid restructuring while directing our focus toward the successful development of FT218, our novel once-nightly therapy for narcolepsy patients,” said Geoffrey Glass, Chairman of Avadel’s Board of Directors.

  • GlobeNewswirelast month

    Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001

    DUBLIN, Ireland, May 22, 2019 (GLOBE NEWSWIRE) --  Avadel Pharmaceuticals plc (AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001. It has been granted Priority Review status by the FDA resulting in a six-month review period. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 15, 2019.

  • Introducing Avadel Pharmaceuticals (NASDAQ:AVDL), The Stock That Tanked 82%
    Simply Wall St.2 months ago

    Introducing Avadel Pharmaceuticals (NASDAQ:AVDL), The Stock That Tanked 82%

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply...

  • Associated Press2 months ago

    Avadel: 1Q Earnings Snapshot

    The Dublin-based company said it had a loss of 35 cents per share. The specialty pharmaceutical company posted revenue of $16.4 million in the period. The company's shares closed at $1.20. A year ago, ...

  • GlobeNewswire2 months ago

    Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results

    REST-ON 63% enrolled; 98 patients remain to be enrolled Jordon Dubow, M.D., appointed as Chief Medical Officer Noctiva™-related assets sold; all operational activities have.

  • ACCESSWIRE2 months ago

    Avadel Pharmaceuticals Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Avadel Pharmaceuticals Plc (NASDAQ: AVDL ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 8:30 AM ...

  • GlobeNewswire2 months ago

    Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results

    DUBLIN, Ireland, April 29, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a.

  • GlobeNewswire2 months ago

    Avadel Pharmaceuticals Announces Appointment of Jordan Dubow, M.D., as Chief Medical Officer

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for sleep disorders, today announced that it has appointed Jordan Dubow, M.D., as Chief Medical Officer. Dr. Dubow brings extensive experience leading clinical development programs in sleep and neurological disorders to Avadel, where he will lead the development of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. “Dr. Dubow’s experience in a wide range of neurological disorders, especially sleep, will be invaluable to Avadel as we continue advancing FT218 toward approval and commercialization,” said Geoff Glass, Chairman of Avadel Pharmaceuticals.

  • Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
    Zacks3 months ago

    Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

    Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.

  • Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
    Zacks3 months ago

    Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

    The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

  • Associated Press3 months ago

    Avadel: 4Q Earnings Snapshot

    The Dublin-based company said it had a loss of $1.72 per share. The specialty pharmaceutical company posted revenue of $20.9 million in the period. For the year, the company reported a loss of $95.3 million, ...

  • GlobeNewswire3 months ago

    Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

    DUBLIN, Ireland, March 15, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results.

  • GlobeNewswire4 months ago

    Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, March 15, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. Avadel Pharmaceuticals plc (AVDL) is a branded specialty pharmaceutical company.  Our primarily focus is on the development and potential FDA approval for FT218 which is in a Phase III clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.  The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

  • GlobeNewswire5 months ago

    Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring

    Avadel Pharmaceuticals plc (AVDL) provided clarification regarding the restructuring actions announced earlier today. The restructuring actions do not trigger a default or violate covenants related to the 4.50% Exchangeable Senior Notes due in 2023.

  • GlobeNewswire5 months ago

    Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program

    Avadel Pharmaceuticals plc (AVDL), today announced a corporate restructuring to assure the financial health required to maximize the value of FT218, currently in Phase III development for the treatment of excessive daytime sleepiness (EDS) and Cataplexy in patients suffering from Narcolepsy. Avadel expects to realize $70 to $75 million in cost reductions in 2019 as compared to 2018 as a result of the restructuring plan, driven primarily by exiting NOCTIVA™. “It is clear that FT218, an investigational, once-nightly formulation of sodium oxybate, is the Company’s most promising and commercially-attractive asset targeting a large orphan market with an estimated value of nearly $1.5 billion in 2018,” said Greg Divis, interim Chief Executive Officer of Avadel.

  • GlobeNewswire5 months ago

    ‘Sleep Normal’ campaign urges Americans to end frequent nighttime urination and stop settling for nights of bad sleep

    WASHINGTON, Jan. 23, 2019 -- A new awareness campaign called ‘Sleep Normal’ launched Monday to raise awareness of nocturia, an underdiagnosed, treatable, medical condition that.

  • Read This Before Selling Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares
    Simply Wall St.5 months ago

    Read This Before Selling Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...

  • GlobeNewswire6 months ago

    Avadel Pharmaceuticals Announces Changes to Management Team and Board of Directors

    - Michael S. Anderson resigns as Chief Executive Officer and member of Avadel’s Board of Directors – - Gregory J. Divis, current Avadel Chief Operating Officer, named Interim.

  • Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
    Zacks6 months ago

    Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA

    Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.

  • GlobeNewswire6 months ago

    Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors

    Avadel Pharmaceuticals plc (AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that Kevin Kotler, the founder and Portfolio Manager of Broadfin Capital, LLC, has been appointed to the Company’s Board of Directors and will immediately join the Board. The Company also intends to nominate and appoint an additional director, in consultation with Broadfin, in the very near future.

  • GlobeNewswire6 months ago

    Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals — Future Expectations, Projections Moving into 2018

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire7 months ago

    As Waking Up Multiple Times a Night to Urinate Can Lead to Memory Deficits, Obesity, Lowered Sex Drive, Falls and Depression, a New Council Urges Awareness and Action

    WASHINGTON, Nov. 29, 2018 -- Nov. 25-30 acknowledges Nocturia Awareness Week, part of Bladder Health Month, which encourages people to take control of their urinary health..